| Jul 29 |
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
|
| Jul 24 |
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
|
| Jul 23 |
Telix Successfully Prices A$650 Million Convertible Bonds
|
| Jul 23 |
Telix Announces A$600 Million Convertible Bonds Offering
|
| Jul 17 |
Telix Pharmaceuticals Q2 2024 Revenue and Business Highlights, Guidance Upgrade
|
| Jul 17 |
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
|
| Jul 11 |
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
|
| Jun 17 |
Radiopharma specialist Telix pulls last-minute plug on $232m IPO
|
| Jun 14 |
Radiopharma drugmaker Telix pulls US IPO plans
|
| Jun 5 |
Telix Announces Launch of Proposed Initial Public Offering in the United States
|
